Translational Study Searching for Synergy between Glycopyrronium and Indacaterol
- 15 September 2014
- journal article
- research article
- Published by Informa UK Limited in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 12 (2), 175-181
- https://doi.org/10.3109/15412555.2014.922172
Abstract
We aimed to explore whether the acute bronchodilation induced by indacaterol 150 μg and glycopyrronium bromide 50 μg is additive or synergistic with respect to monocomponents by testing the type of effect ex vivo on isolated human bronchi and then in vivo in COPD patients. Both indacaterol and glycopyrronium caused a concentration-dependent relaxation of human isolated bronchial tissues sub-maximally pre-contracted with acetylcholine; glycopyrronium was significantly more potent than indacaterol. The analysis of data using the Bliss Independence (BI) criterion indicated that glycopyrronium plus indacaterol produced an additive interaction at the isoeffective concentrations inducing EC20 and a significant synergistic relaxant effect at isoeffective concentrations inducing EC30. In COPD patients, the inhalation of indacaterol and glycopyrronium in combination significantly anticipated at 15 min post-administration the mean peak of bronchodilatory effect compared to the two drugs administered alone. The study of interaction between indacaterol and glycopyrronium by BI analysis evidenced an additive effect for FEV1 between 5 min and 180 min post-inhalation, with synergistic interaction at 15 min post-administration, compared to the bronchodilation induced by these drugs administered alone. This study suggests that the combination ensures a broncholytic effect that is greater than that induced by the single monocomponents.Keywords
This publication has 18 references indexed in Scilit:
- Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN studyRespiratory Medicine, 2013
- Muscarinic receptors on airway mesenchymal cells: Novel findings for an ancient targetPulmonary Pharmacology & Therapeutics, 2013
- Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estableArchivos de Bronconeumología, 2012
- Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomesPrimary Care Respiratory Journal, 2012
- Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnnals of Internal Medicine, 2011
- The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulmonary Pharmacology & Therapeutics, 2010
- Drug interaction: focusing on response surface modelsKorean Journal of Anesthesiology, 2010
- Quantifying synergism/antagonism using nonlinear mixed‐effects modeling: A simulation studyStatistics in Medicine, 2007
- A mathematical approach to study combined effects of toxicants in vitro: Evaluation of the Bliss independence criterion and the Loewe additivity modelToxicology in Vitro, 2007
- Cholinergic and neurogenic mechanisms in obstructive airways diseaseAmerican Journal Of Medicine, 1986